Claims for Patent: 10,106,605

Summary for Patent: 10,106,605

Title:	Compositions and methods for antibodies targeting Epo
Abstract:	The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
Inventor(s):	Ghosh; Joy (Brookline, MA), Rutz; Mark Anthony (Munich, DE), Tissot-Daguette; Kathrin Ulrike (Neuried, DE), Splawski; Igor (Cambridge, MA), Roguska; Michael (Cambridge, MA)
Assignee:	NOVARTIS AG (Basel, CH)
Application Number:	15/180,879
Patent Claims:	1. A method of treating macular edema in a subject comprising administering to said subject, an effective amount of a composition comprising an antibody, or antigen binding fragment thereof, that binds EPO and comprises a) heavy chain variable region HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 4, 5, and 6, respectively; b) heavy chain variable region HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NOs: 21, 22, and 23, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 24, 25, and 26, respectively; c) heavy chain variable region HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NOs: 41, 42, and 43, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 44, 45, and 46, respectively; or d) heavy chain variable region HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NOs: 61, 62, and 63, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 64, 65, and 66, respectively. 2. The method of claim 1, wherein said antibody, or antigen binding fragment thereof, comprises heavy and light chain variable regions having amino acid sequences at least 90% identical to SEQ ID NOs: 13 and 14; SEQ ID NOs: 33 and 34; SEQ ID NOs: 53 and 54; or SEQ ID NOs: 73 and 74, respectively. 3. The method of claim 1, wherein said antibody, or antigen binding fragment thereof, comprises a heavy chain and a light chain with amino acid sequences having at least 90% sequence identity to SEQ ID NOs: 15 and 16; SEQ ID NOs: 35 and 36; SEQ ID NOs: 55 and 56; or SEQ ID NOs: 75 and 76, respectively. 4. The method of claim 1, wherein said antibody, or antigen binding fragment thereof, is a human antibody, a chimeric antibody, a monoclonal antibody, a single chain antibody, Fab, Fab', F(ab')2, Fv or scFv. 5. The method of claim 1, wherein said antibody, or antigen binding fragment thereof, is an IgG isotype. 6. The method of claim 1, wherein administration of said composition decreases retinal vein dilation, decreases vascular leakage, and/or increases blood flow in the eye. 7. The method of claim 1, wherein said method further comprises administering an anti-VEGF antibody or an anti-VEGF receptor antibody. 8. The method of claim 1, wherein said method further comprises administering a second composition, wherein said second composition comprises a compound selected from the group consisting of ranibizumab, bevacizumab, pegaptanib, aflibercept, pazopanib, sorafenib, sunitinib, and rapamycin. 9. The method of claim 8, wherein said second composition comprises ranibizumab. 10. The method of claim 1, wherein the antibody, or antigen binding fragment thereof, comprises heavy chain variable region HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NOs: 21, 22, and 23, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 24, 25, and 26, respectively. 11. The method of claim 1, wherein the antibody, or antigen binding fragment thereof, comprises heavy and light chain variable regions having amino acid sequences at least 90% identical to SEQ ID NOs: 33 and 34, respectively. 12. The method of claim 1, wherein the antibody, or antigen binding fragment thereof, comprises heavy and light chain variable regions having amino acid sequences as set forth in SEQ ID NOs: 33 and 34, respectively. 13. The method of claim 1, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain and a light chain having amino acid sequences with at least 90% sequence identity to SEQ ID NOs: 35 and 36, respectively. 14. The method of claim 1, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain and a light chain having amino acid sequences as set forth in SEQ ID NOs: 35 and 36, respectively.

Details for Patent 10,106,605

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2036-06-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006		2036-06-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012		2036-06-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016		2036-06-13